Search company, investor...
Fibrotech Therapeutics company logo

Fibrotech Therapeutics


Acquired | Acquired



About Fibrotech Therapeutics

Fibrotech is an Australian biopharmaceutical company developing a new class of drugs to prevent a massive health burden associated with fibrosis (tissue scarring). The Company develops novel anti-fibrotic drug candidates for the treatment of the fibrosis prevalent in such chronic conditions as chronic kidney disease, chronic heart failure, pulmonary fibrosis and arthritis. Fibrotech's lead product FT011 is an antifibrotic to prevent the tissue fibrosis associated with diabetic nephropathy. FT011 has successfully completed a Phase Ia trial in healthy volunteers demonstrating safety and tolerability up to doses of 1000mg and a Phase Ib trial is currently underway involving patients with diabetic nephropathy associated with Type 1 or Type 2 diabetes. Diabetic nephropathy is the leading cause of end-stage renal disease, a severe medical condition that can only be managed with dialysis or kidney transplantation. There are several products in preclinical development selected from over 150 analogues, many of which are novel chemical entities and are markedly improved antifibrotic agents. Fibrotech was founded in 2006 and is located in Melbourne Australia.

Headquarters Location

Level 9, 278 Collins Street PO Box 248, Flinders Lane

Melbourne, Victoria, 3000,


+61 3 9288 2546

Missing: Fibrotech Therapeutics's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Fibrotech Therapeutics's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Fibrotech Therapeutics

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Fibrotech Therapeutics is included in 1 Expert Collection, including Diabetes.



1,898 items

Fibrotech Therapeutics Patents

Fibrotech Therapeutics has filed 1 patent.

patents chart

Application Date

Grant Date


Related Topics




Kidney diseases, Vascular diseases, Autoimmune diseases, Inflammations, Rare diseases


Application Date


Grant Date



Related Topics

Kidney diseases, Vascular diseases, Autoimmune diseases, Inflammations, Rare diseases



Latest Fibrotech Therapeutics News

Australian serial entrepreneur Darren Kelly tackles fibrosis yet again in Certa Therapeutics

May 18, 2021

May 18, 2021 PERTH, Australia – Certa Therapeutics Pty Ltd. founder and CEO Darren Kelly knows a thing or two about launching biotech companies. He spun out Fibrotech Therapeutics in 2006 from the University of Melbourne, which was one of the Medical Research Commercialization Fund’s (MRFC) first investments.

Fibrotech Therapeutics Frequently Asked Questions (FAQ)

  • Where is Fibrotech Therapeutics's headquarters?

    Fibrotech Therapeutics's headquarters is located at Level 9, 278 Collins Street, Melbourne.

  • What is Fibrotech Therapeutics's latest funding round?

    Fibrotech Therapeutics's latest funding round is Acquired.

  • Who are the investors of Fibrotech Therapeutics?

    Investors of Fibrotech Therapeutics include Shire and Brandon Capital.

  • Who are Fibrotech Therapeutics's competitors?

    Competitors of Fibrotech Therapeutics include Actinobac Biomed, Anacor Pharmaceuticals, Santarus, Cardiokine, Anthera Pharmaceuticals and 12 more.

Compare Fibrotech Therapeutics to Competitors

Intarcia Therapeutics

Intarcia Therapeutics is a biopharmaceutical company based in Boston, Massachusetts. Intarcia is engaged in the development of a pipeline of products for the proprietary Medici Drug Delivery System comprised of three technologies: A stabilization technology that allows for proteins, peptides, antibody fragments, and other highly potent small molecules to be stabilized at or above human body temperatures, a matchstick-sized osmotic mini-pump that is placed under the dermal layer of skin to deliver a continuous and consistent flow of medication, and a placement technology including proprietary tools designed to provide an optimal user experience.


Cryptopharma is a Company focused on the discovery and development of anti-inflammatory therapeutic agents for treatment of pulmonary diseases. The company's initial focus is on the development of CP92, a treatment of Cystic Fibrosis. Second generation compounds are in development with the potential to treat other inflammatory conditions including asthma and chronic obstructive pulmonary disease (COPD). See


Humanetics is a clinical-stage pharmaceutical company engaged in developing and commercializing products to enhance human health and wellbeing in markets with urgent and unmet needs. It has a focus on radiation modulators for oncology, medical imaging, and medical countermeasure uses. The company develops BIO 300, a highly selective modulator of inflammation, cell cycle arrest, and DNA damage repair. Humanetics was founded in 1988 and is based in Minneapolis, Minnesota.

Icagen Logo

Icagen partners with pharmaceutical and biotechnology companies to offer scientific expertise and access to technologies for ion channel and transporter drug discovery and development. The Icagen team has experience advancing molecules from drug discovery to clinical development across multiple therapeutic areas and ion channel classes. Icagen's tool box comprises a range of cell lines and technologies for ion channel and transporter research, capped by the label-free XRpro platform. XRpro technology, based on X-ray fluorescence, enables high throughput assessment of ion channels and transporters, including challenging systems with high therapeutic interest.


NeurOp is a biopharmaceutical company developing new medicines to treat central nervous system disorders, including major depression, neuropathic pain and ischemia. The company's mission is to develop a new generation of N-methyl-D-aspartate (NMDA) receptor blockers, which inhibit proteins that play an important role in neuron signaling. Its compounds specifically target the NR2B subtype of these receptors offering an unprecedented opportunity to improve the safety and tolerability of this therapeutic class without compromising efficacy.

OcuNexus Therapeutics

OcuNexus Therapeutics is a development stage biopharmaceutical company that develops treatments for front- and back-of-the-eye diseases and disorders.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.